| The Ministry of Health, the Regions, and AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 肝脏
> 肝脏疾病：大多数类型 | 监管合作伙伴关系
> 与监管机构合作 | 10,000 | National | Regularly | 115023591745 |
| Through submissions to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] via the Technical Health Committee of the Ministry of Health. | HIV
> HIV | 监管合作伙伴关系
> 与监管机构合作 | 1,000 | National | Regularly | 115050875230 |
| The organisation represents patients before national and European regulatory bodies, including AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and EMA [European Medicines Agency]. | 稀有
> 罕见病：代谢/溶酶体 | 监管合作伙伴关系
> 与监管机构合作 | 1,000 | National | Regularly | 115050896715 |
| Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services], Ministry of Health, Lazio Region. | 呼吸系统
> 呼吸系统：大多数疾病 | 监管合作伙伴关系
> 与监管机构合作 | 5,000 | National | Sometimes | 115052531440 |
| Yes. The association represents patients' interests before the institutions and regulatory authorities involved in decision-making processes related to healthcare policy, access to therapies, and the sustainability of the healthcare system. | 风湿性
> 风湿性疾病：大多数类型 | 监管合作伙伴关系
> 与监管机构合作 | 100,000 | National | Regularly | 115057561938 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 风湿性
> 风湿性疾病：大多数类型 | 监管合作伙伴关系
> 与监管机构合作 | 100,000 | National | Regularly | 115057561938 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | 心脏
> 心力衰竭 | 监管合作伙伴关系
> 与监管机构合作 | 10,000 | National | Regularly | 115057865983 |
| Approval of medicinal products by AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 呼吸系统
> 肺动脉高压 | 监管合作伙伴关系
> 与监管机构合作 | 100 | National | Rarely | 115060569246 |
| Meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services]. | 肾脏
> 肾脏疾病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | Regional | Sometimes | 114997535217 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], CNS [Consiglio Nazionale della Sanità - National Health Council], the Ministry, Parliament, the Regions, and regulatory bodies. | 免疫
> 原发性免疫缺陷病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Regularly | 115020417471 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 癌症
> 癌症：乳腺癌 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | We do not communicate with patients directly | National | Sometimes | 115035044046 |
| Letters were co-authored and submitted to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] at the request of paediatric nephrologists, seeking compassionate use authorisation for investigational medicinal products. | 稀有
> 罕见病：肾脏 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100 | National | Rarely | 115057369547 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 风湿性
> 风湿性疾病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 115057561938 |
| We are members of the EMA [European Medicines Agency] multi-stakeholder advisory board, and we are frequently invited to participate in the scientific advice committee for the approval of medicines for mitochondrial diseases. | 稀有
> 罕见病：遗传性 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | 100,000 | International | Regularly | 119078073632 |
| Our regional representatives participate in the regional diabetes technical working groups. | 内分泌
> 糖尿病（1型和2型） | 监管合作伙伴关系
> 参与临床指南制定机构 | 10,000 | National | No | 115028521635 |
| We requested meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] on two occasions; one such request, in 2023, was successful. | 癌症
> 癌症：胆管 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100,000 | National | Rarely | 114996625156 |
| Meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services]. | 肾脏
> 肾脏疾病 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | Regional | Sometimes | 114997535217 |
| We request meetings with regional authorities and hospital management bodies responsible for pharmaceutical distribution. | 出血
> 出血性疾病：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100 | Regional | Sometimes | 114997584898 |
| Through meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] to safeguard the continued availability of medicines. | 稀有
> 囊性纤维化 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Regularly | 115005109524 |
| Through the Ministry of Health and the Lombardy Region. | HIV
> HIV | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | Local | Regularly | 115006694528 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], CNS [Consiglio Nazionale della Sanità - National Health Council], the Ministry, Parliament, the Regions, and regulatory bodies. | 免疫
> 原发性免疫缺陷病 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Regularly | 115020417471 |
| We engage in dialogue with the Regional Authority and with the ASP [Aziende Sanitarie Provinciali – Provincial Health Authorities]. | 出血
> 血友病 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100 | Regional | Regularly | 115037242647 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 内分泌
> 糖尿病（1型和2型） | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100 | Local | Sometimes | 115037371533 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 神经系统
> 多发性硬化症 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100,000 | National | Regularly | 115038849633 |
| Through submissions to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] via the Technical Health Committee of the Ministry of Health. | HIV
> HIV | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | National | Regularly | 115050875230 |
| The organisation represents patients before national and European regulatory bodies, including AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and EMA [European Medicines Agency]. | 稀有
> 罕见病：代谢/溶酶体 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | National | Regularly | 115050896715 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 风湿性
> 风湿性疾病：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100,000 | National | Regularly | 115057561938 |
| The organisation [in Italy] actively engaged in challenging the withdrawal of a marketing authorisation for a medicinal product. It contributed to the submission of formal representations to the European Commission urging reconsideration of the withdrawal. | 稀有
> 罕见病：肝脏 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100 | National | Rarely | 115057832320 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | 心脏
> 心力衰竭 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Regularly | 115057865983 |
| We collaborate with other patient associations of a similar nature to advocate for the approval and release of medicines required for our condition. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 1,000 | National | Rarely | 115006753491 |
| Through the UNIAMO [Unione Italiana delle Associazioni di Malati – Italian Federation of Rare Disease Patient Organisations] Federation, with which we are affiliated. | 稀有
> 罕见病：大多数类型 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | National | Regularly | 115055436186 |
| Through a network of associations. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | National | Regularly | 115057092350 |
| We are actively campaigning for the amendment or abolition of Nota 99 [Nota 99 is the Italian Medicines Agency (AIFA) reimbursement guideline for Chronic Obstructive Pulmonary Disease (COPD) maintenance therapies. It regulates the prescription of inhalers, ensuring appropriate diagnosis through spirometry while detailing which treatments GPs can initiate or repeat]. We are also campaigning for vaccination against Respiratory Syncytial Virus (RSV). | 呼吸系统
> 哮喘和慢性阻塞性肺病 | 影响政策和立法
> 影响医疗保健政策和立法 | 5,000 | National | Regularly | 114996865765 |
| Active participation in the drafting and approval of legislation in support of the disease area. | 总体健康
> 肥胖症 | 影响政策和立法
> 影响医疗保健政策和立法 | 10,000 | National | Regularly | 115012927513 |
| Cardiovascular Alliance — Ministry of Health. | 心血管
> 心血管：大多数类型 | 影响政策和立法
> 影响医疗保健政策和立法 | 100 | Regional | Sometimes | 115028352096 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | 骨骼
> 骨骼：其他 | 影响政策和立法
> 影响医疗保健政策和立法 | 100 | National | Regularly | 115037246562 |
| Yes. The association represents patients' interests before the institutions and regulatory authorities involved in decision-making processes related to healthcare policy, access to therapies, and the sustainability of the healthcare system. | 风湿性
> 风湿性疾病：大多数类型 | 影响政策和立法
> 影响医疗保健政策和立法 | 100,000 | National | Regularly | 115057561938 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | 骨骼
> 骨骼：其他 | 影响政策和立法
> 参与公众听证会和咨询 | 100 | National | Regularly | 115037246562 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 内分泌
> 糖尿病（1型和2型） | 影响政策和立法
> 参与公众听证会和咨询 | 100 | Local | Sometimes | 115037371533 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. Relationship with Ministries (Health, Welfare, Disability). | 神经系统
> 多发性硬化症 | 影响政策和立法
> 动员议员和政治领导人 | 100,000 | National | Regularly | 115038849633 |
| Cross-Party Parliamentary Group — IVT [Intravitreal Therapy] Technical Working Group. Cataract Technical Working Group — Regional Partnerships — Local Activities. | 视觉障碍
> 视觉障碍 | 影响政策和立法
> 动员议员和政治领导人 | 1,000 | National | Regularly | 115056238448 |
| Active participation in the drafting and approval of legislation in support of the disease area. | 总体健康
> 肥胖症 | 影响政策和立法
> 参与起草公共卫生法规 | 10,000 | National | Regularly | 115012927513 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | 心脏
> 心力衰竭 | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 10,000 | National | Regularly | 115057865983 |
| Market authorisation for "Koselugo" [used to treat neurofibromatosis type 1 (NF1)] should be extended to adult patients, given that it is currently approved only for paediatric cases where surgery is not an option. | 神经系统
> 神经纤维瘤病（NF） | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 1,000 | National | Sometimes | 115060431887 |
| Organisation of educational camps, disease prevention, regulatory-compliant monitoring [in Italy], and waiting list management. | 未指定
> 未指定 | 定价与可负担性倡导
> 跟踪和监控药品定价/药品短缺 | 100 | Local | Regularly | 115037563159 |
| Specifically at the level of the regional health authority, we have engaged in advocacy for the extension of the prescribability of Baqsimi (nasal glucagon) to be also reimbursable for adult diabetic patients. | 内分泌
> 糖尿病（1型和2型） | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | Local | Sometimes | 115023236354 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 内分泌
> 糖尿病（1型和2型） | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | Local | Sometimes | 115037371533 |
| Our work focuses on securing reimbursement for medicines, not on pricing. | 神经退行性
> 痴呆症 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100,000 | National | Rarely | 115060441597 |
| Organisation of educational camps, disease prevention, regulatory-compliant monitoring [in Italy], and waiting list management. | 未指定
> 未指定 | 定价与可负担性倡导
> 参与宣传活动 | 100 | Local | Regularly | 115037563159 |
| Competitive tender for diabetes medical devices and supplies. | 内分泌
> 糖尿病（1型和2型） | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | Regional | Rarely | 114997517950 |
| We request meetings with regional authorities and hospital management bodies responsible for pharmaceutical distribution. | 出血
> 出血性疾病：大多数类型 | 改善访问路径
> 促进公平获取药品/医疗保健 | 100 | Regional | Sometimes | 114997584898 |
| Through meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] to safeguard the continued availability of medicines. | 稀有
> 囊性纤维化 | 改善访问路径
> 促进公平获取药品/医疗保健 | 10,000 | National | Regularly | 115005109524 |
| We collaborate with other patient associations of a similar nature to advocate for the approval and release of medicines required for our condition [blood cancers]. | 癌症
> 癌症：血液 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Rarely | 115006753491 |
| Extension of the indications for the use of Baqsimi, indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged one year and above with diabetes mellitus. | 内分泌
> 糖尿病（1型和2型） | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | Regional | Sometimes | 115021346889 |
| At the regional health authority level in particular, advocacy efforts were undertaken to extend the prescribability of Baqsimi (nasal glucagon) to include reimbursement for adult patients with diabetes. Additionally, participation in the competitive tendering process for diabetes medical devices and supplies — including reagent test strips, continuous glucose monitoring sensors, and insulin pumps — was pursued. | 内分泌
> 糖尿病（1型和2型） | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | Local | Sometimes | 115023236354 |
| At the regional health authority level in particular, advocacy efforts were undertaken to extend the prescribability of Baqsimi (nasal glucagon) to include reimbursement for adult patients with diabetes. Additionally, participation in the competitive tendering process for diabetes medical devices and supplies — including reagent test strips, continuous glucose monitoring sensors, and insulin pumps — was pursued. | 内分泌
> 糖尿病（1型和2型） | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | Local | Sometimes | 115023236354 |
| The association is at the forefront of efforts to ensure that all patients receive the appropriate therapy and that treatment is applied consistently at the national level. | 视觉障碍
> 视神经脊髓炎 | 改善访问路径
> 促进公平获取药品/医疗保健 | 100 | National | Regularly | 115024933081 |
| Meetings with FG [Focus Group] to improve community-based diabetology services. | 内分泌
> 糖尿病（1型和2型） | 改善访问路径
> 促进公平获取药品/医疗保健 | 100 | Local | Sometimes | 115032223368 |
| We are seeking early access for the drug vorasidenib [oral cancer therapy for people with gliomas]. | 癌症
> 癌症：脑 | 改善访问路径
> 促进公平获取药品/医疗保健 | 100 | National | Sometimes | 115050882510 |
| Formal request letters to expedite access to medicines. | 癌症
> 癌症：妇科 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Sometimes | 115055638865 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 风湿性
> 风湿性疾病：大多数类型 | 改善访问路径
> 促进公平获取药品/医疗保健 | 100,000 | National | Regularly | 115057561938 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] or regional health authorities regarding delays in the market access of medicines. | 癌症
> 癌症：妇科 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Rarely | 115060470442 |
| We are campaigning for vaccination against Respiratory Syncytial Virus (RSV) [in Italy]. | 呼吸系统
> 哮喘和慢性阻塞性肺病 | 改善访问路径
> 倡导更广泛的疫苗获取渠道 | 5,000 | National | Regularly | 114996865765 |
| Specifically at the level of the regional health authority, we have engaged in advocacy for the extension of the prescribability of Baqsimi (nasal glucagon) to be also reimbursable for adult diabetic patients. | 内分泌
> 糖尿病（1型和2型） | 改善访问路径
> 解决访问和管理方面的差距 | 1,000 | Local | Sometimes | 115023236354 |
| The association is at the forefront of efforts to ensure that all patients receive the appropriate therapy and that treatment is applied consistently at the national level. | 视觉障碍
> 视神经脊髓炎 | 改善访问路径
> 解决访问和管理方面的差距 | 100 | National | Regularly | 115024933081 |
| We are an integral part of the Innovative Medicines Group of the Veneto Region [part of Veneto Region's governance structure for evaluating and managing access to innovative medicines]. | 癌症
> 癌症：血液 | 改善访问路径
> 解决访问和管理方面的差距 | 1,000 | National | Regularly | 115053421236 |
| Regional disparities in access to treatment and enrolment in therapeutic management plans. | 神经系统
> 癫痫 | 改善访问路径
> 解决访问和管理方面的差距 | 1,000 | Regional | Sometimes | 115063172483 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | 骨骼
> 骨骼：其他 | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 100 | National | Regularly | 115037246562 |
| Letters were co-authored and submitted to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] at the request of paediatric nephrologists, seeking compassionate use authorisation for investigational medicinal products [for rare kidney conditions]. | 稀有
> 罕见病：肾脏 | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 100 | National | Rarely | 115057369547 |
| The organisation [in Italy] actively engaged in challenging the withdrawal of a marketing authorisation for a medicinal product. It contributed to the submission of formal representations to the European Commission urging reconsideration of the withdrawal. | 稀有
> 罕见病：肝脏 | 诊断与药品配送
> 确保安全有效地使用药物 | 100 | National | Rarely | 115057832320 |
| Our regional representatives participate in the regional diabetes technical working groups. | 内分泌
> 糖尿病（1型和2型） | 诊断与药品配送
> 参与制定临床指南 | 10,000 | National | No | 115028521635 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. | 神经系统
> 多发性硬化症 | 诊断与药品配送
> 参与制定临床指南 | 100,000 | National | Regularly | 115038849633 |
| By participating in the regional coordination body that sits on the regional working table. | 内分泌
> 糖尿病（1型和2型） | 机构治理
> 确保在政府咨询机构中的代表性 | 100 | Regional | Rarely | 115019671886 |
| Regional health councillors, prescribing physicians, hospital pharmacists, regional drug directors, and representation at regional stakeholder forums. | 风湿性
> 风湿性疾病：大多数类型 | 机构治理
> 确保在政府咨询机构中的代表性 | 100,000 | National | Regularly | 115031446886 |
| We collaborate with institutional decision-makers, policymakers, and clinicians within a technical working group. | 内分泌
> 糖尿病（1型和2型） | 机构治理
> 确保在政府咨询机构中的代表性 | 100 | Local | Regularly | 115037426004 |
| We maintain regular contact with the relevant offices of the Tuscany Regional Authority. | 出血
> 血友病 | 机构治理
> 确保在政府咨询机构中的代表性 | 100 | Regional | Regularly | 115043798242 |
| Represent patients before national and European regulatory bodies — including AIFA [Agenzia Italiana del Farmaco, the Italian Medicines Agency] and EMA [European Medicines Agency] — as well as national health institutions and local authorities. | 稀有
> 罕见病：代谢/溶酶体 | 机构治理
> 确保在政府咨询机构中的代表性 | 1,000 | National | Regularly | 115050896715 |
| In an advisory capacity, when consulted by the local and regional health authority (Azienda Sanitaria Locale). | 内分泌
> 糖尿病（1型和2型） | 机构治理
> 确保在政府咨询机构中的代表性 | 100 | Local | Rarely | 115060756578 |
| We are members of the EMA [European Medicines Agency] multi-stakeholder advisory board, and we are frequently invited to participate in the scientific advice committee for the approval of medicines for mitochondrial diseases. | 稀有
> 罕见病：遗传性 | 机构治理
> 确保在政府咨询机构中的代表性 | 100,000 | International | Regularly | 119078073632 |
| By participating in the regional coordination body that sits on the regional working table. | 内分泌
> 糖尿病（1型和2型） | 机构治理
> 在多利益相关方网络中高效协作 | 100 | Regional | Rarely | 115019671886 |
| Participated alongside Public Institutions in the Stroke Observatory. | 脑血管
> 描边 | 机构治理
> 在多利益相关方网络中高效协作 | 5,000 | National | Regularly | 115019690819 |
| Participated alongside Public Institutions in the Stroke Observatory. | 脑血管
> 描边 | 机构治理
> 在多利益相关方网络中高效协作 | 5,000 | National | Regularly | 115019690819 |
| Regional health councillors, prescribing physicians, hospital pharmacists, regional drug directors, and representation at regional stakeholder forums. | 风湿性
> 风湿性疾病：大多数类型 | 机构治理
> 在多利益相关方网络中高效协作 | 100,000 | National | Regularly | 115031446886 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 内分泌
> 糖尿病（1型和2型） | 机构治理
> 在多利益相关方网络中高效协作 | 100 | Local | Sometimes | 115037371533 |
| We collaborate with institutional decision-makers, policymakers, and clinicians within a technical working group. | 内分泌
> 糖尿病（1型和2型） | 机构治理
> 在多利益相关方网络中高效协作 | 100 | Local | Regularly | 115037426004 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. Relationship with Ministries (Health, Welfare, Disability). | 神经系统
> 多发性硬化症 | 机构治理
> 在多利益相关方网络中高效协作 | 100,000 | National | Regularly | 115038849633 |
| Healthcare protection, consumer protection, and other related areas. | 总体健康
> 医疗服务 | 维护患者权益/提高生活质量
> 保护/改善患者体验 | 1,000 | Regional | Regularly | 115038525050 |
| Documentation requirements for the renewal of driving licences for individuals with diabetes. | 内分泌
> 糖尿病（1型和2型） | 维护患者权益/提高生活质量
> 保护/改善患者体验 | Do not know | Regional | Sometimes | 115046244188 |
互动
行动与倡导
31 提及
